Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EUBF | ISIN: US83548R3030 | Ticker-Symbol: H3D
NASDAQ
28.03.24
15:42 Uhr
1,840 US-Dollar
0,000
0,00 %
1-Jahres-Chart
SONNET BIOTHERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
SONNET BIOTHERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur SONNET BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.03.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy at the AACR 2024 Annual Meeting199PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs...
► Artikel lesen
11.03.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy Met the Study's Initial Pre-Specified Objective208Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON-080 was reviewed by the study's Data Safety Monitoring Board (DSMB)The adverse event profile and tolerability...
► Artikel lesen
06.03.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report2
29.02.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers311PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today...
► Artikel lesen
14.02.Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended in December - Earnings Summary2
14.02.Sonnet BioTherapeutics GAAP EPS of -$0.31, revenue of $18.63M1
14.02.Sonnet BioTherapeutics GAAP EPS of -$0.311
14.02.Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update295Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offeringExtensive preclinical data on SON-1210 published in Frontiers in ImmunologyReceived approval...
► Artikel lesen
14.02.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report1
14.02.Sonnet BioTherapeutics Holdings, Inc. - 10-Q, Quarterly Report6
13.02.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 44.200The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameUS42328V8019 HELIUS...
► Artikel lesen
29.01.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report4
27.12.23Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report4
22.12.23Sonnet BioTherapeutics files for $100M mixed shelf6
21.12.23Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy266PRINCETON, NJ / ACCESSWIRE / December 21, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today...
► Artikel lesen
15.12.23Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended in September - Earnings Summary4
14.12.23Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report4
14.12.23Sonnet BioTherapeutics Holdings, Inc. - 10-K, Annual Report1
14.12.23Sonnet BioTherapeutics GAAP EPS of -$18.14 beats by $9.99, revenue of $0.15M in-line3
14.12.23Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update608PRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic...
► Artikel lesen
Seite:  Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1